In this issue:
Therapeutic vulnerability of MM to pri-miR-17-92 inhibition
Elotuzumab monotherapy for smouldering MM
Characterising immunoparesis in newly diagnosed MM: impact on PFS and OS
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis vs. MM
Elotuzumab + pomalidomide/dexamethasone for MM
Patient-reported health-related QOL from TOURMALINE-MM1
Second-line lenalidomide + dexamethasone therapy in real-world MM
Identification of novel mutational drivers reveals oncogene dependencies in MM
Maintenance treatment and survival in myeloma
Thalidomide before and after autologous SCT in recently diagnosed MM
Please login below to download this issue (PDF)